At ALS TDI, our comprehensive approach to ALS research spans every aspect of drug discovery and therapeutic development. Right now we have more active research programs and collaborations than ever, but none of these programs happen in isolation. Every advancement—whether testing promising therapies, exploring mRNA technologies, pioneering ALS studies, or uncovering critical biomarkers—works together to move us closer to a future without ALS. These are our active research initiatives.

The ALS Therapy Development Institute (ALS TDI) is pleased to announce its acceptance as a member of DataCite, a leading global organization dedicated to ensuring research is openly available and accessible across scientific disciplines. This partnership will significantly enhance the discoverability, accessibility, and citability of the ALS Research Collaborative (ARC) dataset, a vital resource in the global search for effective ALS treatments.

While there are currently no effective treatments to stop ALS progression, there are now three drugs available that provide some benefits to people living with ALS.